AGC Biologics and Gore Collaborate on New Protein A-based Purification Technology and Contract Manufacturing Services for Antibody Therapies
12. Dezember 2022 08:37 ET
|
AGC Biologics
Seattle, Dec. 12, 2022 (GLOBE NEWSWIRE) -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced a collaboration with W.L....
InvestorBrandNetwork Announces The Dealmaker Show Interview with Tryp Therapeutics Inc. CEO Greg McKee
03. August 2021 08:00 ET
|
InvestorBrandNetwork (IBN)
LOS ANGELES, Aug. 03, 2021 (GLOBE NEWSWIRE) -- via InvestorWire – InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities, today announces...
Momenta Pharmaceuticals Announces Date of First Quarter 2018 Financial Results Conference Call and Webcast
01. Mai 2018 08:00 ET
|
Momenta Pharmaceuticals, Inc.
CAMBRIDGE, Mass., May 01, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), today announced that it will release its financial results for the first quarter ended March 31, 2018...
XOMA to Present at the Biotechnology Industry Organization BIO CEO & Investor Conference on February 9, 2009
02. Februar 2009 08:00 ET
|
XOMA Corporation
BERKELEY, Calif., Feb. 2, 2009 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of antibody therapeutics, announced today that Steven Engle, Chairman and Chief...
Chelsea Therapeutics Initiates Phase I Clinical Trial of CH-4051
13. November 2008 07:30 ET
|
Chelsea Therapeutics
CHARLOTTE, N.C., Nov. 13, 2008 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) has begun dosing volunteers in the single ascending dose (SAD) study of its Phase I clinical...
Oakwood Laboratories Offers Contract Manufacturing for Injectable Pharmaceutical Products
11. November 2008 11:01 ET
|
Oakwood Laboratories, LLC
CLEVELAND, Nov. 11, 2008 (GLOBE NEWSWIRE) -- Oakwood Laboratories, LLC, an emerging specialty pharmaceutical company focused on advanced injectable drug delivery, today announced it is offering...
Threshold Pharmaceuticals Reports Third Quarter 2008 Financial Results
06. November 2008 16:00 ET
|
Threshold Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Nov. 6, 2008 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today reported financial results for the third quarter ended September 30, 2008. The net loss for...
Nabi Biopharmaceuticals Announces Successful Final Results of NicVAX(r) Immunogenicity Study
29. Oktober 2008 09:25 ET
|
Nabi Biopharmaceuticals
ROCKVILLE, Md., Oct. 29, 2008 (GLOBE NEWSWIRE) -- Nabi Biopharmaceuticals (Nasdaq:NABI) announced today positive final results from its Phase 2 NicVAX(r) (Nicotine Conjugate Vaccine) schedule...
Hemispherx Engages The Sage Group as Its Corporate Partnership Advisor for Ampligen to Treat Chronic Fatigue Syndrome
06. Oktober 2008 14:29 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Oct. 6, 2008 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (Amex:HEB) today announced that it has engaged The Sage Group to assist Hemispherx to identify, select, negotiate, and close a...
New Programs Added in Antibody Collaboration Between XOMA and Takeda
15. September 2008 16:35 ET
|
XOMA Corporation
BERKELEY, Calif., Sept. 15, 2008 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of antibody therapeutics, announced today the initiation of new therapeutic...